Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report [0.03%]
拉米夫定与利福平在暴露于结核病的婴儿体内的药代动力学相互作用：案例报告
Marlotte Aa van der Veer,Tom G Jacobs,Laura H Bukkems et al.
Marlotte Aa van der Veer et al.
We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy d...
Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand [0.03%]
欧洲和泰国既往接受过治疗的HIV感染儿童和青少年使用埃替拉韦为基础抗逆转录病毒治疗结局的研究
European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc,Alex Lyons,Lindsay Thompson et al.
European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc et al.
Background: Etravirine (ETR) is approved as a component of second or third-line antiretroviral treatment (ART) for children living with HIV. We assessed the outcomes of ETR-based ART in children in routine care in Europe ...
The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study [0.03%]
稳定接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者肾骨轴的亚组分析：GS-US-104-0423研究的结果
Elena Alvarez,Lucy Campbell,Willard Tinago et al.
Elena Alvarez et al.
Background: Data on low bone mineral density (BMD) in people living with HIV (PLWH) are mainly derived from younger adults; little is known about how antiretroviral therapy (ART) and alterations in the renal-bone axis rel...
Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi [0.03%]
马拉维近期感染HIV的孕妇中非核苷类逆转录酶抑制剂耐药水平
George Bello,Matthew Kagoli,Sikhona Chipeta et al.
George Bello et al.
Background: Information on HIV drug resistance (HIVDR) prevalence in people newly diagnosed with HIV is limited. We implemented a cross-sectional study to estimate HIVDR prevalence among pregnant women recently infected w...
Progress in the quality of care for newly diagnosed people with HIV in Spain (2004-2019) [0.03%]
西班牙新诊断HIV感染者的关怀质量改善（2004-2019年）
Belén Alejos,Cristina Díez,María J Galindo et al.
Belén Alejos et al.
Background: We monitored the quality of care for newly diagnosed people with HIV (PWH) in Spain, including linkage to care within 1 month of HIV diagnosis (LC-1Mo) and viral suppression within 3 months of HIV diagnosis (V...
Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV [0.03%]
整合酶抑制剂相关机体组成差异很大程度上可由社会经济地位解释——针对慢性HIV感染男性患者的调查研究
Julie K Wisch,Sarah A Cooley,Kevin E Yarasheski et al.
Julie K Wisch et al.
Background: Substantial body composition alterations have been reported after starting combined antiretroviral therapy (cART). We characterized a cohort of chronically infected and virologically suppressed (VL < 50 copies...
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B [0.03%]
JNJ-73763989 的药代动力学和安全性：在健康日本成人和非日本成人中针对乙型肝炎病毒的肝脏定向 siRNA，以及与 JNJ-56136379 和核苷[酸]类似物联用治疗慢性乙型肝炎患者的疗效
Ed Gane,Man-Fung Yuen,Thomas N Kakuda et al.
Ed Gane et al.
Background: JNJ-73763989 comprises two hepatitis B virus (HBV)-specific, liver-targeted N-galactosamine-conjugated short interfering RNA triggers, JNJ-73763976 and JNJ-73763924. JNJ-73763989 pharmacokinetics, safety and t...
Randomized Controlled Trial
Antiviral therapy. 2022 Jun;27(3):13596535221093856. DOI:10.1177/13596535221093856 2022
Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey [0.03%]
卢旺达接受一线抗逆转录病毒治疗的成人获得性人类免疫缺陷病毒药物耐药性横断面全国代表性调查
Gentille Musengimana,Elysee Tuyishime,Athanase Kiromera et al.
Gentille Musengimana et al.
Background: We assessed the prevalence of acquired HIV drug resistance (HIVDR) and associated factors among patients receiving first-line antiretroviral therapy (ART) in Rwanda. ...
Rebecca Roediger,Elizabeth Kula Smyth,Douglas Dieterich
Rebecca Roediger
Adefovir, a nucleotide analog developed by John Martin, was a major breakthrough in the treatment of chronic Hepatitis B. Prior to adefovir, Hepatitis B treatment was limited to two therapeutic modalities, either interferon, which carried s...
Uli Schmitz,Swami Swaminathan
Uli Schmitz
John Martin's untimely death in March 2021 was a huge loss for us personally, Gilead Sciences, the company he built over 30 years and the scientific community concerned with antiviral therapies. We wish to honor John's legacy by retelling t...